Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTX-463 in Healthy Adult Males
NCT07450521Phase 1Completed
- Sponsor
- Mediar Therapeutics
- Start
- Feb 2026
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) and cancer comparing MTX-463 with Placebo (2 arms). Primary endpoints: Area Under the Plasma Concentration Versus Time Curve From Time Zero to t at 22 days and Maximum Observed Plasma Concentration at 22 days. Started Feb 2026; status: completed.
02
Drugs
MTX-463
03
Conditions
idiopathic pulmonary fibrosis (IPF)cancer
Beyond the preview
Go deeper on NCT07450521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07450521.